Moderate additive immunosuppressive effect of thalidomide combined with cyclosporin A in rat cardiac transplantation

Transplant Immunology

Volumn 4, Issue 3, 1996, Pages 241-246

  Ostraat O ^a   Qi, Zhongquan ^b   Gannedahl, Göran ^c   Tufveson, Gunnar ^c   Ekberg, Henrik ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; ROQUINIMEX; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030248759     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(96)80024-4     Document Type: Article

References (34)

1. 1 Wanders A, Gerdin B, Tufvesson G. Abolition of the effect of cyclosporin on rat cardiac allograft rejection by the new immunomodulator LS-2616 (linomide). Transplantation 1989; 47: 216-17.
2. 2 Wanders A, Vogt P, Karlsson-Parra A, Wonigkeit K, Gerdin B, Tufvesson G. Evidence that LS-2616 (linomide) causes acute rejection of rat allografts protected by cyclosporin but not of long-term surviving allografts. Transplantation 1991; 52: 234-38.
3. 3 Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol 1990; 144: 4472-76.
4. 4 Stålhandske T, Erikson E, Sandberg B-M. A novel quinolinecar-boxamide with interesting immunomodulatory activity. Int J Immunopharmacol 1982; 4: 336.
5. 5 Johnsson C, Tufveson G. The immunomodulator LS-2616 (linomide) more effectively than sensitization of the donor enhances graft-versus-host reaction after small bowel transplantation. Transplant Immunol 1994; 2: 56-60.
6. 6 Bengtsson M, Simonsson B, Carlsson K et al. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplantation. Transplantation 1992; 53: 882-88.
7. 7 Gannedahl G, Wanders A, Carlsson M, Tufvesson G. 15-Deoxyspergualin, effects in rat heart allograft transplantation - relation to dose, timing and cyclosporine. Transplantation 1993; 55: 455-56.
8. 8 Tufvesson G, Gannedahl G, Johnsson C, Olausson M, Wanders A, Ekberg H. New immunosuppressants: testing and development in animal models and the clinic: with special reference to DSG. Immunol Rev 1993; 36: 99-109.
9. 9 Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
10. 10 Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80.
11. 11 Weglicki WB, Stafford RE, Dickens BF, Tong Mak I, Cassidy MM, Phillips TM. Inhibition of tumor necrosis factor-alpha by thalidomide in magnesium deficiency. Mol Cell Biochem 1993; 129: 195-200.
12. 12 Keenan RJ, Eiras G, Burckart GJ et al. Immunosuppressive properties of thalidomide. Transplantation 1991; 52: 908-10.
13. 13 Vogelsang GB, Hess AD, Santos GW. Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant 1988; 3: 393-98.
14. 14 Östraat Ö, Riesbeck K, Eriksson T, Schatz H, Ekberg H. Thalidomide prolonged graft survival in a rat cardiac transplant model, but had no inhibitory effect on lymphocyte function in vitro. Transplant Immunol 1996; 4: 117-25.
15. 15 Olausson M, Mjörnstedt L, Lindholm L, Brynger H. Non suture organ grafting to neck vessels in rat. Acta Chir Scand 1984; 15: 463-67.
16. 16 Hellmann K, Duyke DJ, Tucker DF. Prolongation of skin homograft survival by thalidomide. Br Med J 1965; 2: 687-89.
17. 17 Tamura F, Vogelsang GB, Reitz BA, Baumgartner WA, Herskowitz A. Combination thalidomide and cyclosporin for cardiac allograft rejection. Transplantation 1990; 49: 20-25.
18. 18 Emre S, Sumrani N, Hong J. Beneficial effect of thalidomide and ciclosporine combination in heterotopic cardiac transplantation in rats. Eur Surg Res 1990; 22: 336-39.
19. 19 Vogelsang GB, Wells MC, Santos GW, Chen TL, Hess AD. Combination low-dose thalidomide and cyclosporin prophylaxis for acute graft-versus-host disease in a rat mismatched model. Transplant Proc 1988; 20 (suppl 2): 226-228.
20. 20 Vogelsang GB, Hess AD, Gordon G, Santos GW. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation 1986; 41: 644-47.
21. 21 Murphy GP, Brede HD, Weber HW, Groenewaid JH, Williams PD. Thalidomide immunosuppression in canine renal allotransplantation. J Med 1970; 1: 66-73.
22. 22 Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 5974-78.
23. 23 Pober J. Effects of tumor necrosis factor and related cytokines on vascular endothelial cells. In: Bock G, Marsh J eds. Tumor necrosis factor and related cytokines. New York: Wiley, 1987: 88.
24. 24 Ranges GE, Figari IS, Espevik T, Palladino MA Jr. Inhibition of cytotoxic T cell development by transforming growth factor-α and reversal by recombinant tumor necrosis factor-α. J Exp Med 1987; 166: 991-98.
25. 25 Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF) α: induction of TNF receptors on human T cells and TNF-α mediated enhancement of T cell responses. J Immunol 1987; 138: 1786-90.
26. 26 Arbustini E, Grasso M, Diegoli M et al. Expression of tumor necrosis factor in human acute cardiac rejection. Am J Pathol 1991; 4: 709-15.
27. 27 Lin H, Chensue S, Strieter RM et al. Antibodies against tumor necrosis factor prolong cardiac allograft survival in the rat. J Heart Lung Transplant 1992; 11: 330-35.
28. 28 Seu P, Imagawa DK, Wasef E et al. Monoclonal anti-tumor necrosis factor-α antibody treatment of rat cardiac allografts: synergism with low-dose cyclosporin and immunohistological studies. J Surg Res 1991; 50: 520-28.
29. 29 Gonzalo JA, Gonzalés-Garcia A, Kalland T, Hedlund G, Martinés-A C, Kroemer G. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol 1993; 23: 2372-74.
30. 30 Karussis DM, Lehmann D, Slavin S et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 1993; 90: 6400-404.
31. 31 Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol 1990; 144: 129-35.
32. 32 Spetz-Hagberg AL, Larsson-Sciard EL. Decreased levels of pathogenic IgG anti-DNA antibodies in autoimmune mice after linomide treatment. Res Immunol 1989; 140: 517-25.
33. 33 Larsson E-L, Joki A, Stålhandske T. Mechanism of action of the new immunomodulator LS2616 on T cell responses. Int J Immunopharmacol 1987; 9: 425-31.
34. 34 Gonzalo JA, Gonzáles-Garcia A, Kalland T, Hedlund G, Martinez-A C, Kroemer G. Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur J Immunol 1994; 24: 48-52.